Dr. Kunlin Cao, President of Keya Medical R&D, participated in the Cardiovascular Disease Imaging Forum at QICCD 2020 alongside Dr. Pengfei Zhang of Shangdong University.
Dr. Kunlin Cao delivered a keynote address at the China AI in Medical Imaging Conference on Keya Medical’s experience bringing AI-powered medical imaging solutions to clinical use.
Recent research demonstrates applications for CCTA to be used as the default test for evaluating patients with stable chest pain.
On Sept. 18, Keya Medical was recognized as the winner of of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.
On Sept. 10, Keya Medical was invited to deliver an academic lecture to more than 130 imaging departments in honor of the newly established Northern Jiangsu People’s Hospital Medical Imaging Alliance.
During QICC 2020, Dr. Xinyang Hu delivered a special lecture on the clinical significance of non-invasive CT-FFR.
The European Society of Cardiology (ESC) Congress 2020 revealed opportunities and challenges in cardiovascular imaging AI.
ESC Updated Guidelines on Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation
The European Society of Cardiology published new clinical practice guidelines on managing acute coronary syndromes in patients.
Keya Medical announced on Aug. 13 that it has raised over $20 million in Series B+ funding.
DeepVessel FFR was successfully implemented in Luohe Sixth People’s Hospital.
The National Medical Products Administration (NMPA) in China has published new documents regarding the approval of medical AI products.
On March 20, the research results of Keya Medical’s COVID-19 AI Assisted Diagnosis algorithm were published in the peer-reviewed journal Radiology.